Reported Standalone quarterly numbers for Sun Pharma Advanced Research Company are:
Net Sales at Rs 27.19 crore in March 2025 up 64.19% from Rs. 16.56 crore in March 2024.
Story continues below Advertisement
Quarterly Net Loss at Rs. 60.98 crore in March 2025 up 42.84% from Rs. 106.69 crore in March 2024.
EBITDA stands negative at Rs. 53.92 crore in March 2025 up 47.71% from Rs. 103.12 crore in March 2024.
Sun Pharma Adv shares closed at 167.03 on May 16, 2025 (NSE) and has given -14.77% returns over the last 6 months and -22.60% over the last 12 months.
Story continues below Advertisement
| Sun Pharma Advanced Research Company | | Standalone Quarterly Results | in Rs. Cr. |
|
| Mar'25 | Dec'24 | Mar'24 | | Net Sales/Income from operations | 27.19 | 14.91 | 16.56 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 27.19 | 14.91 | 16.56 | | EXPENDITURE | | Consumption of Raw Materials | 5.70 | 4.58 | 7.46 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | -- | -- | -- | | Power & Fuel | -- | -- | -- | | Employees Cost | 24.83 | 26.41 | 26.72 | | Depreciation | 2.55 | 2.75 | 2.69 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 50.58 | 58.30 | 89.90 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -56.47 | -77.13 | -110.21 | | Other Income | -- | 0.19 | 4.40 | | P/L Before Int., Excpt. Items & Tax | -56.47 | -76.94 | -105.81 | | Interest | 4.51 | 2.77 | 0.88 | | P/L Before Exceptional Items & Tax | -60.98 | -79.71 | -106.69 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | -60.98 | -79.71 | -106.69 | | Tax | -- | -- | -- | | P/L After Tax from Ordinary Activities | -60.98 | -79.71 | -106.69 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -60.98 | -79.71 | -106.69 | | Equity Share Capital | 32.45 | 32.45 | 32.45 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -1.88 | -2.46 | -3.29 | | Diluted EPS | -1.88 | -2.46 | -3.29 | | EPS After Extra Ordinary | | Basic EPS | -1.88 | -2.46 | -3.29 | | Diluted EPS | -1.88 | -2.46 | -3.29 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
